Navigation Links
Stanford discovery may eliminate potentially lethal side effect of stem cell therapy
Date:8/14/2011

STANFORD, Calif. - Like fine chefs, scientists are seemingly approaching a day when they will be able to make nearly any type of tissue from human embryonic stem cells. You need nerves or pancreas, bone or skin? With the right combination of growth factors, skill and patience, a laboratory tissue culture dish promises to yield therapeutic wonders. But within these batches of newly generated cells lurks a big potential problem: Any remaining embryonic stem cells - those that haven't differentiated into the desired tissue - can go on to become dangerous tumors called teratomas when transplanted into patients.

Now researchers at the Stanford University School of Medicine have developed a way to remove these pluripotent human embryonic stem cells from their progeny before the differentiated cells are used in humans. ("Pluripotent" describes cells that are able to become all types of adult tissue.)

"The ability to do regenerative medicine requires the complete removal of tumor-forming cells from any culture that began with pluripotent cells," said Irving Weissman, MD, director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine. "We've used a combination of antibodies to weed out the few undifferentiated cells that could be left in the 10 or 100 million differentiated cells that make up a therapeutic dose."

Weissman pointed out that the production of therapeutic cells from pluripotent stem cells for regenerative medicine was a major goal of Proposition 71, the ballot measure that established the California Institute for Regenerative Medicine to allocate $3 billion to advance stem cell science. CIRM funded this research.

The scientists believe the technique could also be used to remove residual tumor-initiating cells from populations of cells derived from induced pluripotent stem, or iPS, cells. These cells may also be useful for therapy but, unlike embryonic stem cells, iPS cells are created in the laboratory from adult tissue.

"Commonly used differentiation protocols for embryonic stem and iPS cells often give rise to mixed cultures of cells," said research associate Micha Drukker, PhD. "Because even a single undifferentiated cell harbors the ability to become a teratoma, we sought to develop a way to remove these cells before transplantation."

Drukker is the senior author of the research, which will be published online Aug. 14 in Nature Biotechnology. Stanford medical student Chad Tang is the first author. Weissman, who is also the Virginia and D.K. Ludwig Professor for Clinical Investigation and Cancer Research and a member of the Stanford Cancer Institute, is a co-author. The research was conducted in his lab.

Teratomas are the Frankensteins of the tumor world - a hodgepodge of tissues like teeth, hair and bone. They owe their remarkable composition to the fact that the cells from which they arise early in development are pluripotent. In fact, the ability to form teratomas in animals is a defining feature of true pluripotent cells.

But the very feature that confirms a cell's pluripotency also makes it potentially dangerous to use therapeutically. That's why Tang, Drukker and Weissman decided to try to develop an antibody that would recognize and bind to only pluripotent cells and enable their removal from a mixture of cells. Although a few such antibodies already existed, they were not specific enough on their own to completely weed out the tumor-causing cells.

The researchers studied two sets of antibodies - one commercially available and one they generated themselves - to identify which among them bound most strongly to pluripotent, but not differentiated, cells. They found one newly generated antibody that was highly specific for a previously unknown marker on undifferentiated cells that they termed stage-specific embryonic antigen-5, or SSEA-5. The cells bound by this antibody, anti-SSEA-5, expressed high levels of pluripotent-specific genes and resembled embryonic stem cells in appearance. Anti-SSEA-5 also bound strongly to the inner cell mass of an early human embryo, the group of cells from which embryonic stem cell lines are derived.

When the researchers injected human embryonic stem cells recognized by anti-SSEA-5 into mice, they found that in seven out of seven times, the cells formed rapidly growing teratomas. However, cells that were not bound by anti-SSEA-5 formed smaller teratomas in only three of 11 experiments. Combining anti-SSEA-5 with two other antibodies known to bind to pluripotent cells completely separated the pluripotent from the differentiated cells, although the researchers did see some smaller, less-diverse growths in some cases.

Upon analysis, Tang and his colleagues found that anti-SSEA-5 recognizes and binds to a cell-surface carbohydrate structure called a glycan. As the pluripotent cell differentiates, this glycan is modified to other glycan structures not recognized by the antibody.

"The study of glycans is becoming an active area of stem cell biology," said Tang. "Many glycans are highly expressed in embryonic stem cells, but not in differentiated cells. This warrants further study and may lead to new understandings about embryonic stem cell biology."

In addition to Tang, Drukker and Weissman, other Stanford researchers who participated in the study include graduate student Andrew Lee; postdoctoral scholar Jens-Peter Volkmer, MD; instructor of pathology Debashis Sahoo, PhD; undergraduate student Divya Nag; research assistant Adriane Mosley; research associate Matthew Inlay; instructor of medicine Reza Ardehali, MD; postdoctoral scholar Shawn Chavez, PhD; professor of obstetrics and gynecology and director of Stanford's Human Embryonic Stem Cell Research and Education Center Renee Reijo Pera, PhD; professor of obstetrics and gynecology Barry Behr, PhD; and associate professor of cardiovascular medicine and of radiology Joseph Wu, MD, PhD.

Stanford University has filed for patent protection for the use of monoclonal antibody-based protocols to remove teratogenic pluripotent stem cells from a cell mixture.


'/>"/>

Contact: Krista Conger
kristac@stanford.edu
650-725-5371
Stanford University Medical Center
Source:Eurekalert

Related medicine news :

1. Rhoads Named Director of Cancer Outreach Programs For Stanford Cancer Center, Cancer Prevention Institute of California
2. Interleukin Genetics, Inc. and Stanford University Report Genetic Test Improves Weight Loss Success With Diets
3. Mathematical innovation turns blood draw into information gold mine in Stanford study
4. Nanoscale stealth probe slides into cell walls seamlessly, say Stanford engineers
5. Eating disorder cutoffs miss some of sickest patients, Stanford/Packard study finds
6. Plant pathogen genetically tailors attacks to each part of host, say Stanford researchers
7. Stanford-led team validates, extends fMRI research on brain activity
8. Stanford/Packard study finds surprising disparity in where chronically ill kids hospitalized
9. Orphaned elderly serious casualty of African AIDS epidemic, Stanford study finds
10. Pro Ana Versus Pro Recovery Sites: New Study by Johns Hopkins and Stanford University raises concerns.
11. Melanoma-initiating cell identified by Stanford scientists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... , ... April 24, 2017 , ... Come to PAINWeekEnd ... 4200 Jim Walter Blvd, for an educational and exciting 2-day program. , An ... staff hearing this before they approach patients” about the course entitled Ain't Misbehavin': Decreasing ...
(Date:4/24/2017)... ... April 24, 2017 , ... Donna Parker, L. Ac. reads ... not found any of them to be very practical. She wanted to write a ... make changes in their health. It prompted her in writing “ A Clear Path ...
(Date:4/24/2017)... ... , ... “Reflections of God’s Work”: an enlightening collection of life lessons leading ... of published author, Jerri Broglin, a survivor of great loss who gained insight on ... eye-opener for those searching for answers, as we are finding the answers that are ...
(Date:4/24/2017)... , ... April 24, 2017 , ... “The Saint with ... with Trin, and Omega Station” is the creation of published author, Chris Jackson. ... Metroplex where he works in the Dallas Independent School District teaching English. He is ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Life of ... University of Florida. The event will be held at 7:30 pm on May 10th ... Block and Drew Copeland of Sister Hazel, will support the UF Collegiate Recovery Community ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... Calif. , April 19, 2017  IRIDEX Corporation ... will release financial results for the first quarter 2017 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
Breaking Medicine Technology: